Neuroglee Therapeutics

Neuroglee is a health tech startup that wants to help with a digital therapeutic platform created to treat patients in the early stages of the disease.

Neuroglee Therapeutics discovers, develops, and commercializes software as medical treatment for patients with neurodegenerative diseases.

Neuroglee was founded in 2020 by Aniket Singh Rajput. The company is headquartered in Singapore.


Neuroglee’s adaptive learning tech uses machine learning and biomarkers related to cognitive function, mood and behavior to automatically personalize therapy plans for each patient, who access the software through a smartphone or tablet.


Neuroglee's digital therapeutics and monitoring tools help preserve cognition and independence while providing more accurate and consistent insight into drug efficacy, facilitating accelerated drug development.


Neuroglee's lead product, NG-001, is prescription digital therapeutics software intended for the treatment of early-stage Alzheimer's disease that can be used independently or in conjunction with pharmacotherapy.


Neuroglee is backed by Openspace Ventures, EDBI, Ramen Singh, former CEO of Mundipharma; Biofourmis co-founders Kuldeep Singh Rajput and Wendou Liu; and Eisai Co.. The company raised $10M in Series A round on Sep 09, 2021. This brings Neuroglee's total funding to $12.3M to date.



  • Year founded: 2020
  • Funding Info: $12.3M over 2 Rounds (Latest Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Singapore
  • State: Central Region
  • Country: Singapore
Related businesses